Clinical Trials and Preclinical Infrastructure Asset Map - Life Sciences

78
BRITISH COLUMBIA
Staffing of the Centre is as follows:
Study Nurses/
Coordinators 1
Research Assistants
3
Data Managers/
Coordinators
Pharmacy
Staff
Laboratory
Staff
Admin.
6* 4 0 0 2 (part-time) 2** 2***
* 4 coordinators; 2 nurses.
** 1 project manager, 1 CTU manager.
*** 1 statistician, 1 IT technician.
IT/ Statistics
Clinical trials are conducted at the clinic, which also uses external laboratories, hospitals and pharmacies
in its conduct of trials. It has a laboratory at UBC, as well as its own laboratory space.
Quality control/ assurance procedures are based on extensive Standard Operating Procedures and
Good Clinical Practice guidelines of Health Canada and the FDA. The unit also provides regular training
sessions for researchers and staff members in the conduct of clinical studies. All projects are approved
by the REB prior to initiation.
Contact:
Tossonian, Harout. Research Manager. Tel: 604-642-6429 x 304. tossonian@exchange.ubc.ca.
Diabetes Research Centre
The Diabetes Research Centre (http://diabetesresearch.net/) is located next to VGH.
The Principal Investigator and Research Director is Dr. Tom Elliott. His details can be found in Appendix
6. The Centre has five clinical trial coordinators. Studies include the testing of novel drugs in patients
with diabetes, diabetes with or at risk of cardiovascular disease.
Contact:
Elliott, Tom. Research Director. Tel: 604-875-5934. tom.elliott@vch.ca.
Epilepsy Clinic
The VGH Epilepsy Clinic is targeted at adults with epilepsy and related disorders (http://vch.eduhealth.
ca/PDFs/FM/FM.470.V279.pdf ). It contains both in-patient and out-patient components. Principal Investigators
include the following, whose details can be found in Appendix 6:
• Javidan, Mano
• Townsend, Tiffany.
Contact:
Javidan, Mano. Medical Director EEG Lab. Tel: 604 875-4402. manouchehr.javidan@vch.ca.
Hematology Research and Clinical Trials Unit (HRCTU)
The HRCTU is part of the Leukemia/BMT Program of B.C (www.leukemiabmtprogram.org). It conducts
Phases I, II, and III clinical trials on all hematologic malignancies and also works with stem cells. The Unit
sees approximately 500 new patients each year and approximately 100 of these may be suitable for